



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office :

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Date: 10th October, 2020

To
The Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai -400001

To
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G
Bandra Kurla Complex,
Bandra (E)
Mumbai - 400051

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Sub: Update on USFDA inspection of Shilpa Medicare Ltd.'s Jadcherla Manufacturing Facility in Telangana.

Ref: BSE: 530549 / Stock Symbol: NSE: SHILPAMED

Dear Sir,

This is to inform that the Company, has received a warning letter yesterday i.e on 9th October 2020 at 10:06 PM (India Time) through email from the USFDA for its Jadcherla facility, Telangana.

We will be engaging with the agency and are fully committed in resolving this issue at the earliest. The Company is also committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities.


The Company believes that the warning letter will have minimum impact of disruption of supplies and the existing revenues from operations of this facility.

Shilpa Medicare Ltd currently has three manufacturing facilities approved by USFDA - One formulation facility and two API facilities. None of these facilities except Jadcherla has any outstanding issues with the USFDA at this point of time.

This is for your information and records please.

Thanking you,

Yours faithfully,
For Shilpa Medicare Limited


V V Krishna Chaitanya
Company Secretary and Compliance officer

